Oncotarget

Meta-Analysis:

Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors

Liping Lin _, Juanjuan Zhao, Ning Kong, Yan He, Jiazhu Hu, Fuxi Huang, Jianjun Han and Xiaolong Cao

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:57379-57385. https://doi.org/10.18632/oncotarget.18283

Metrics: PDF 2099 views  |   HTML 2267 views  |   ?  


Abstract

Liping Lin1,4,*, Juanjuan Zhao2,*, Ning Kong3,4, Yan He1,4, Jiazhu Hu1,4, Fuxi Huang1,4, Jianjun Han1,4 and Xiaolong Cao1,4

1Department of Oncology, Panyu Central Hospital, Guangzhou, 511400, China

2School of Nursing, Sun Yat-sen University, Guangzhou, 510000, China

3Department of Ophthalmology, Panyu Central Hospital, Guangzhou, 511400, China

4Cancer Institute of Panyu, Guangzhou, 511400, China

*These authors contributed equally to this work

Correspondence to:

Liping Lin, email: [email protected]

Keywords: ALK-TKIs, interstitial lung disease, QTc prolongation, non-small-cell lung cancer, meta-analysis

Received: April 16, 2017     Accepted: May 03, 2017     Published: May 29, 2017

ABSTRACT

Background: To conduct a systematic review and meta-analysis to assess the overall incidence and risk of interstitial lung disease (ILD) and QTc prolongation associated with anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (-TKIs) in non-small-cell lung cancer (NSCLC) patients.

Results: A total of 1,770 patients from 8 clinical trials were included. The incidences of high-grade ILD and QTc prolongation was 2.5% (95% CI 1.7-3.6%), and 2.8% (95% CI 1.8-4.3%), respectively. Meta-analysis demonstrated that the use of ALK-TKIs in NSCLC patients significantly increased the risk of developing high-grade ILD (Peto OR, 3.27, 95%CI: 1.18–9.08, p = 0.023) and QTc prolongation (Peto OR 7.51, 95% CI, 2.16–26.15; p = 0.002) in comparison with chemotherapy alone.

Materials and Methods: A systematic literature search was performed to identify related citations up to January 31, 2017. Data were extracted, and summary incidence rates, Peto odds ratios (Peto ORs), and 95% confidence intervals (CIs) were calculated.

Conclusions: The use of ALK-TKIs significantly increases the risk of developing high-grade ILD and QTc prolongation in lung cancer patients. Clinicians should pay attention to the risks of severe ILD and QTc prolongation with the administration of these drugs.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18283